Compare BKSY & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BKSY | IMMP |
|---|---|---|
| Founded | 2013 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Radio And Television Broadcasting And Communications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 658.3M | 264.9M |
| IPO Year | N/A | N/A |
| Metric | BKSY | IMMP |
|---|---|---|
| Price | $19.19 | $2.88 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $29.00 | N/A |
| AVG Volume (30 Days) | 1.3M | ★ 1.9M |
| Earning Date | 11-06-2025 | 02-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $101,731,000.00 | $3,306,742.00 |
| Revenue This Year | $8.51 | $292.48 |
| Revenue Next Year | $31.31 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 31.28 |
| 52 Week Low | $6.15 | $1.32 |
| 52 Week High | $33.20 | $3.53 |
| Indicator | BKSY | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 51.46 | 64.44 |
| Support Level | $18.40 | $2.52 |
| Resistance Level | $23.74 | $3.32 |
| Average True Range (ATR) | 1.81 | 0.22 |
| MACD | 0.14 | 0.04 |
| Stochastic Oscillator | 38.11 | 58.91 |
BlackSky Technology Inc is a provider of real-time geospatial intelligence. The company delivers on-demand, high-frequency imagery, monitoring, and analytics of some of the critical and strategic locations, economic assets, and events in the world. It designs, owns, and operates one of the industry's low earth orbit (LEO) small satellite constellations, optimized to capture imagery cost-efficiently where and when its customers need it. its Spectra AI software platform processes data from BlackSky's constellation and other third-party sensors to develop the critical insights and analytics that provide its customers with the actionable intelligence. Geographically, the company operates in North America, the Middle East, Asia, and Others.
Immutep Ltd is a Phase three clinical biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-004, TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.